Selection of Germline Genetic Testing Panels in Patients with Cancer: ASCO Guideline

Nadine Tung, Charité Ricker, Hans Messersmith, Judith Balmaña, Susan Domchek, Elena Martinez Stoffel, Khaldoun Almhanna, Banu Arun, Yanin Chavarri-Guerra, Stephanie A. Cohen, Deborah Cragun, Katherine D. Crew, Michael J. Hall, Gregory Idos, Ghecemy Lopez, Tuya Pal, Sara Pirzadeh-Miller, Colin Pritchard, Huma Q. Rana, Umang SwamiGregory A. Vidal

Research output: Contribution to journalArticlepeer-review

13 Scopus citations

Abstract

ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO Guidelines Methodology Manual. ASCO Guidelines follow the ASCO Conflict of Interest Policy for Clinical Practice Guidelines.Clinical Practice Guidelines and other guidance ("Guidance") provided by ASCO is not a comprehensive or definitive guide to treatment options. It is intended for voluntary use by providers and should be used in conjunction with independent professional judgment. Guidance may not be applicable to all patients, interventions, diseases, or stages of diseases. Guidance is based on review and analysis of relevant literature and is not intended as a statement of the standard of care. ASCO does not endorse third-party drugs, devices, services, or therapies and assumes no responsibility for any harm arising from or related to the use of this information. See complete disclaimer in Appendix 1 and Appendix 2 (online only) for more.PURPOSETo guide use of multigene panels for germline genetic testing for patients with cancer.METHODSAn ASCO Expert Panel convened to develop recommendations on the basis of a systematic review of guidelines, consensus statements, and studies of germline and somatic genetic testing.RESULTSFifty-two guidelines and consensus statements met eligibility criteria for the primary search; 14 studies were identified for Clinical Question 4.RECOMMENDATIONSPatients should have a family history taken and recorded that includes details of cancers in first- and second-degree relatives and the patient's ethnicity. When more than one gene is relevant based on personal and/or family history, multigene panel testing should be offered. When considering what genes to include in the panel, the minimal panel should include the more strongly recommended genes from Table 1 and may include those less strongly recommended. A broader panel may be ordered when the potential benefits are clearly identified, and the potential harms from uncertain results should be mitigated. Patients who meet criteria for germline genetic testing should be offered germline testing regardless of results from tumor testing. Patients who would not normally be offered germline genetic testing based on personal and/or family history criteria but who have a pathogenic or likely pathogenic variant identified by tumor testing in a gene listed in Table 2 under the outlined circumstances should be offered germline testing.Additional information is available at www.asco.org/molecular-testing-and-biomarkers-guidelines.

Original languageEnglish (US)
Pages (from-to)2599-2615
Number of pages17
JournalJournal of Clinical Oncology
Volume42
Issue number21
DOIs
StatePublished - Jul 20 2024

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Selection of Germline Genetic Testing Panels in Patients with Cancer: ASCO Guideline'. Together they form a unique fingerprint.

Cite this